2cig: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Isoniazid is a key drug used in the treatment of tuberculosis. Isoniazid | Isoniazid is a key drug used in the treatment of tuberculosis. Isoniazid is a pro-drug, which, after activation by the katG-encoded catalase peroxidase, reacts nonenzymatically with NAD(+) and NADP(+) to generate several isonicotinoyl adducts of these pyridine nucleotides. One of these, the acyclic 4S isomer of isoniazid-NAD, targets the inhA-encoded enoyl-ACP reductase, an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Here we show that the acyclic 4R isomer of isoniazid-NADP inhibits the M. tuberculosis dihydrofolate reductase (DHFR), an enzyme essential for nucleic acid synthesis. This biologically relevant form of the isoniazid adduct is a subnanomolar bisubstrate inhibitor of M. tuberculosis DHFR. Expression of M. tuberculosis DHFR in Mycobacterium smegmatis mc(2)155 protects cells against growth inhibition by isoniazid by sequestering the drug. Thus, M. tuberculosis DHFR is the first new target for isoniazid identified in the last decade. | ||
==About this Structure== | ==About this Structure== | ||
| Line 16: | Line 16: | ||
[[Category: Aladegbami, B.]] | [[Category: Aladegbami, B.]] | ||
[[Category: Argyrou, A.]] | [[Category: Argyrou, A.]] | ||
[[Category: Blanchard, J | [[Category: Blanchard, J S.]] | ||
[[Category: Vetting, M | [[Category: Vetting, M W.]] | ||
[[Category: 1DG]] | [[Category: 1DG]] | ||
[[Category: GOL]] | [[Category: GOL]] | ||
| Line 30: | Line 30: | ||
[[Category: tuberculosis]] | [[Category: tuberculosis]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:49:00 2008'' | ||
Revision as of 14:49, 21 February 2008
|
DIHYDROFOLATE REDUCTASE FROM MYCOBACTERIUM TUBERCULOSIS INHIBITED BY THE ACYCLIC 4R ISOMER OF INH-NADP A DERIVATIVE OF THE PRODRUG ISONIAZID.
Overview
Isoniazid is a key drug used in the treatment of tuberculosis. Isoniazid is a pro-drug, which, after activation by the katG-encoded catalase peroxidase, reacts nonenzymatically with NAD(+) and NADP(+) to generate several isonicotinoyl adducts of these pyridine nucleotides. One of these, the acyclic 4S isomer of isoniazid-NAD, targets the inhA-encoded enoyl-ACP reductase, an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Here we show that the acyclic 4R isomer of isoniazid-NADP inhibits the M. tuberculosis dihydrofolate reductase (DHFR), an enzyme essential for nucleic acid synthesis. This biologically relevant form of the isoniazid adduct is a subnanomolar bisubstrate inhibitor of M. tuberculosis DHFR. Expression of M. tuberculosis DHFR in Mycobacterium smegmatis mc(2)155 protects cells against growth inhibition by isoniazid by sequestering the drug. Thus, M. tuberculosis DHFR is the first new target for isoniazid identified in the last decade.
About this Structure
2CIG is a Single protein structure of sequence from Mycobacterium tuberculosis with SO4, 1DG and GOL as ligands. Active as Dihydrofolate reductase, with EC number 1.5.1.3 Known structural/functional Site: AC1. Full crystallographic information is available from OCA.
Reference
Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid., Argyrou A, Vetting MW, Aladegbami B, Blanchard JS, Nat Struct Mol Biol. 2006 May;13(5):408-13. Epub 2006 Apr 30. PMID:16648861
Page seeded by OCA on Thu Feb 21 16:49:00 2008
